temsirolimus (Torisel)

DRUG2 trials

Sponsors

Pfizer, Emory University

Conditions

Brain NeoplasmsRenal Cell Carcinoma

Phase 1

Assessment of Systemically Administered Torisel Delivery to Brain Tumors by Intratumoral Microdialysis

WithdrawnNCT00949026

Emory UniversityBrain Neoplasms

Start: 2009-07-31End: 2010-05-31Updated: 2013-11-21

Phase 3

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib

CompletedNCT00474786

PfizerRenal Cell Carcinoma

Start: 2007-09-30End: 2013-01-31Updated: 2013-11-21

Related Papers

A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.

2019-02-095 citations

A new prognostic model for overall survival (OS) in second line (2L) for metastatic renal cell carcinoma (mRCC): Development and external validation

Annals of Oncology2018-10-01

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

2016-05-2624 citations

Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database.

Journal of Clinical Oncology2014-02-014 citations

Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement.

2011-07-0722 citations